- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | BofA-Studie treibt Aktie von Bicara Therapeutics an | 2 | Investing.com Deutsch | ||
| Mo | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET | 1 | GlobeNewswire (USA) | ||
| 04.03. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 4 | GlobeNewswire (USA) | ||
| 26.02. | Bicara Therapeutics closes $172.5 million stock offering | 1 | Investing.com | ||
| 26.02. | Bicara Therapeutics schließt Aktienplatzierung über 172,5 Millionen US-Dollar ab | 3 | Investing.com Deutsch | ||
| 26.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 1 | GlobeNewswire (USA) | ||
| 25.02. | Bicara Therapeutics prices $150 million stock offering at $16 | 2 | Investing.com | ||
| 25.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
| 24.02. | Bicara Therapeutics kündigt Aktienemission im Wert von 150 Millionen US-Dollar an | 1 | Investing.com Deutsch | ||
| 24.02. | Bicara Therapeutics launches $150 million stock offering | 2 | Investing.com | ||
| 24.02. | Bicara Therapeutics launches $150M public stock offering | 1 | Seeking Alpha | ||
| 24.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 23.02. | Bicara Therapeutics stock rating reaffirmed by Citizens at Market Outperform | 2 | Investing.com | ||
| 20.02. | Bicara Therapeutics: Citizens bestätigt "Market Outperform"-Rating und Kursziel von 31 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.02. | Bicara Therapeutics stock rating maintained at Market Outperform by Citizens | 1 | Investing.com | ||
| 19.02. | Bicara Therapeutics Inc.: Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen | 1 | GlobeNewswire (USA) | ||
| 19.02. | Bicara Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 05.02. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 29.01. | Citizens initiates coverage on Bicara Therapeutics stock with Market Outperform rating | 1 | Investing.com | ||
| 29.01. | Bicara Therapeutics: Citizens startet Coverage mit "Market Outperform" und hohem Kursziel | 2 | Investing.com Deutsch |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 34,940 | 0,00 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,605 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 27,560 | +2,87 % | Block & Leviton LLP: Travere Therapeutics ALERT: Securities Fraud Investigation by Block & Leviton Could Allow TVTX Investors to Recover Losses | Boston, Massachusetts--(Newsfile Corp. - January 16, 2026) - Block & Leviton is investigating Travere Therapeutics, Inc. (NASDAQ: TVTX) for potential securities law violations. Investors who have... ► Artikel lesen | |
| MAZE THERAPEUTICS | 31,800 | 0,00 % | Maze Therapeutics: BTIG bestätigt Kaufempfehlung nach positiven Studiendaten | ||
| APOGEE THERAPEUTICS | 78,55 | +7,63 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 35,550 | 0,00 % | Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts 'Upbeat' | ||
| BEAM THERAPEUTICS | 23,110 | 0,00 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| ARCELLX | 114,53 | -0,11 % | Arcellx legt Zahlen vor - Augenmerk liegt auf Gilead-Übernahme | ||
| EVOTEC | 4,356 | 0,00 % | EQS-News: Evotec SE: Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer klinischen Studie | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec erhält 10 Mio. $ Meilensteinzahlung von Bristol Myers Squibb im Rahmen der Protein-Degradation-Partnerschaft nach Start einer... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,950 | +15,58 % | Summit Therapeutics (SMMT) Climbs 15.4% Ahead of Pipeline Q2 Updates | ||
| ERASCA | 15,990 | +9,18 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| TYRA BIOSCIENCES | 36,740 | +1,02 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,880 | 0,00 % | RBC Capital raises 4D Molecular stock price target on pipeline progress | ||
| COGENT BIOSCIENCES | 36,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| NUVALENT | 97,98 | +1,90 % | Nuvalent, Inc.: Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results | Commercial preparations well underway to support potential U.S. launch of zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC population, pending FDA review... ► Artikel lesen |
BICARA THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 18,680 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.